Navigation Links
Breaking Study: ICU Medical, Inc. ChemoClave® System Costs Less to Implement than any Closed System Transfer Device for the Safe Handling of Hazardous Drugs
Date:11/8/2011

Texium/Smartsite with $239,020; OnGuard with $393,978; EquaShield with $435,473; and PhaSeal with $507,287. The acquisition cost difference between the most expensive system studied (PhaSeal), and the least expensive system (ChemoCLAVE) was calculated to be $307,005, a difference of 153.3 percent. In addition, the ChemoClave system was shown to generate 1,229 pounds less waste than the PhaSeal system, second only to the Texium/SmartSite system, which generated 214 pounds less waste annually than ChemoClave but cost nearly $40,000 more per year to implement.

"As economic pressures increase, procurement decisions can no longer rely solely on clinical efficacy studies that fail to also assess cost-effectiveness. Limiting waste volume generation to the lowest practical amount is also a major objective for facilities due to its toxicity and adverse implications to the environment," the researchers concluded. "In the absence of current, reliable comparative data on commercially available CSTDs, this evaluation of costs and waste may be used to guide organizations in the implementation of a CSTD."

In a March 2011 editorial in Journal of Oncology Pharmacy Practice, the authors concluded that "If, in fact, the different closed systems currently available are equally effective, then the choice comes down to cost and ease of use." In addition, the editorial urged hospitals to make sure that the CSTD they choose "is capable of containing the hazardous drug throughout all handling steps from reconstitution to administration."(1) To that end, a recent study comparing all commercially available CSTDs found that ChemoCLAVE provided significant cost savings to hospitals while scoring highest in terms of ease of use, practicality, and perceived safety by a cross-functional evaluation team of pharmacists, nurses, and value analysis professionals.(2)

In addition, as the world's only 100% needlefree system, ChemoClave completely and totally eliminates the ris
'/>"/>

SOURCE ICU Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Volcano Corporation Announces Upcoming Presentation of Late-Breaking Clinical Trial Results and FFR Product Launch at TCT 2011
2. Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterologys 76th Annual Meeting
3. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine
4. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration
5. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
6. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
7. Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis
8. Groundbreaking Report Details the New $80 Billion Accountable-Care Market
9. International Dyslexia Association Announces Groundbreaking Parent Membership Initiative in Response to 40,000 Annual Inquiries
10. ERA-EDTA Congress 2011: Late Breaking Clinical Trials II
11. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Following a bipartisan vote in the House ... the Medicare DMEPOS Competitive Bidding Improvement Act of ... released a statement praising the Committee,s work and ... "Today,s mark-up of the Competitive Bidding ... Committee is a critical step forward for this ...
(Date:2/27/2015)... 27, 2015 An aggressive campaign to reduce ... rate of infection with a dangerous drug-resistant bacteria at ... Clostridium difficile, or C.diff, is a bacterium that can ... the colon. A recent article in the New England ... in the United States " asserts ...
(Date:2/27/2015)... - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), ... for its first quarter ended December 31, 2014. ... 2014, revenue was $1,336,685. Operating expenses were $1,063,393.  Net ... share.  Covalon,s President and CEO, ... the significant progress we have made over the past ...
Breaking Medicine Technology:Bidding Fix Takes Major Step Forward After Bipartisan Vote of House Ways and Means Committee 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
...  Boston Scientific Corporation (NYSE: BSX ) ... Chromium Coronary Stent System demonstrated non-inferior results in ... at one year compared to the PROMUS Element™ ... First Human Use Trial.  The trial reported one-year ...
... is pleased to announce the acquisition of Assured Packaging, ... custom manufacturer of aerosols for the health and beauty ... Assured Packaging acquisition and the purchase of K-G Spray-Pak ... most diversified custom aerosol filler in Canada. ...
Cached Medicine Technology:One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 2One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 3One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 4One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 5One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent 6PLZ Aeroscience Acquires Assured Packaging 2
(Date:3/2/2015)... WI (PRWEB) March 02, 2015 ... consultancy focused on quality, regulatory and technical consulting, ... as Chief Operating Officer. , Before joining ... experience leading R&D teams in all aspects of ... leadership positions at Covidien (Medtronic), Regulatory Compliance Associates ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 A true renaissance ... leader of the 1960s cult rock band Khazad Doom, has ... his determination to persevere despite all odds. His motto throughout ... matter what situation or goal was before him. And that ... is now being passed on to a new generation. , ...
(Date:3/2/2015)... 2015 In light of the FDA's ... Xarelto (rivaroxaban) tablets, Ford & Associates Nationwide Legal ... for future users, but may come too late for ... the drug. The FDA has now included the term ... on Xarelto's label. The term “cytolytic hepatitis” has also ...
(Date:3/2/2015)... What are the best practices for writing ... are interviews scheduled, how can physicians best prepare, and ... practicing physicians who are looking for new opportunities can ... the PracticeLink Physician Career Advancement Workshop and Job Fair ... from 5:30 to 8:30 p.m. at the Marriott-Texas Medical ...
(Date:3/2/2015)... Bangladesh (PRWEB) March 02, 2015 The ... of fire safety expert Mark Chubb to serve as ... fire safety operations and training in Bangladesh and guide ... source. , “Mark will ensure that the Alliance ... fire safety programs for Bangladesh garment workers,” said Alliance ...
Breaking Medicine News(10 mins):Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 2Health News:Cult Rock Star’s “Got To Make It” Attitude Inspires New Generations 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 2Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 3Health News:Ford & Associates Nationwide Legal Services, A.P.C., Comments on Xarelto Lawsuits Upon FDA Revisions 4Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2Health News:Alliance for Bangladesh Worker Safety Names New Chief Safety Officer 2
... front of TV, computer linked to less bonding with peers, ... Too much time in front of computers or televisions increases ... parents and peers, a new study suggests. , The researchers ... who provided details about how they spent their free time ...
... resulting aspirin therapy, may not be needed for healthier patients ... study raises questions about the value of both the ankle-brachial ... blood vessel problems in the legs, and the common practice ... ankle-brachial index (ABI) measures blood pressure in the arm and ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... ...
... , ... , ... , , , , ... ...
Cached Medicine News:Health News:Screen Time May Take a Toll on Kids' Relationships 2Health News:Study Questions Value of Test for Peripheral Artery Disease 2Health News:Study Questions Value of Test for Peripheral Artery Disease 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 2Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 3Health News:Sodexo Names Patricia Bellinger to North America Advisory Board 4Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 2Health News:IDEXX Laboratories Elects Joseph Vumbacco as Director 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 2Health News:AMA Honors Maine Governor John Baldacci With Top Government Service Award 3
... Liquichek Qualitative Urine Toxicology Control is ... qualitative rapid urine drug screen panels, including ... (DOA) test kits like Bio-Rad TOX/See, Biosite ... includes qualitative results (+/) for popular kits ...
... Stain is an aqueous new ... in manual methods of reticulocyte ... a one year shelf life ... can be used in conjunction ...
... Liquichek ToRCH Plus IgM ... potential problems in your ToRCH ... affect your test results. Liquichek ... the perfect complement to Liquichek ...
... Liquichek ToRCH Plus Control is ... to monitor the performance of ... instruments and assays. A weak ... allow you to monitor the ...
Medicine Products: